Elaboration and characterisation of novel low-cost adsorbents from grass-derived sulphonated lignin

AbstractThis study investigated the use of water-soluble sulphonated lignin (SL) extracted from grass, which has not been used before as a precursor of activated carbon (AC). Chemical activation of SL with three dehydrating salts (ZnCl2, KCl, Fe2(SO4)3·xH2O) at various salt concentrations (10%, 20%, 30%w/w), charring temperatures (600,700°C) and charring times (1,2h) has been carried out. The surface characteristics and removal efficiencies of cadmium, copper and zinc ions from aqueous solutions were affected by the activation conditions. The sulphonated lignin-based activated carbons (SLACs) with the highest specific surface area, total pore and micropore volume were produced at the lowest dehydrating salt concentration (10%w/w) and at 700°C and 2-h charring. These optimal sulphonated lignin-based ACs were named SLAC-ZC (optimal grass-derived SLAC activated by zinc chloride); SLAC-PC (optimal grass-derived SLAC activated by potassium chloride) and SLAC-FS (optimal grass-derived SLAC activated by ferric sulphate). The central composite design and surface response methodology of different SLACs characteristics showed that the optimal responses were achieved at the same operating conditions. These SLACs also achieved the highest removal efficiencies of Cd2+, Cu2+ and Zn2+ ions from aqueous solutions. The chemical activation had significantly increased the total porosity, microporosity and surface area of water-soluble SL. The activation mechanism depended on the used dehydrating salt where the porosity developed by the dehydration effect of ZnCl2, and by a series of hydrolysis and redox reactions for the other two salts. The results of this research demonstrated that water-soluble SL has a great potential as a novel precursor for the production of activated carbons

INCIDENCE OF THYROID GLAND DISORDERS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

22nd Congress of the European-Hematology-Association -- JUN 22-25, 2017 -- Madrid, SPAINWOS: 000404127005282…European Hematol Asso

The role of azacitidine in the treatment of elderly patients with acute myeloid leukemia: Results of a retrospective multicenter study [Akut miyeloid lösemili yaşlı hastaların tedavisinde azasitidinin rolü: Retrospektif çok merkezli bir çalışmanın sonuçları]

PubMedID: 27095141Objective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective multicenter study, 130 patients of ?60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included. Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment. Median overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of <2, increasing number of AZA cycles (?5 courses), and any HI predicted better OS. Age, AML type, and BM blast percentage had no impact. Conclusion: We conclude that AZA is effective and well tolerated in elderly comorbid AML patients, irrespective of BM blast count, and HI should be considered a sufficient response to continue treatment with AZA. © 2016, Turkish Society of Hematology. All rights reserved

The role of azacitidine in the treatment of elderly patients with acute myeloid leukemia: Results of a retrospective multicenter study [Akut miyeloid lösemili yaşlı hastaların tedavisinde azasitidinin rolü: Retrospektif çok merkezli bir çalışmanın sonuçları]

PubMed ID: 27095141Objective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective multicenter study, 130 patients of ?60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included. Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment. Median overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of <2, increasing number of AZA cycles (?5 courses), and any HI predicted better OS. Age, AML type, and BM blast percentage had no impact. Conclusion: We conclude that AZA is effective and well tolerated in elderly comorbid AML patients, irrespective of BM blast count, and HI should be considered a sufficient response to continue treatment with AZA. © 2016, Turkish Society of Hematology. All rights reserved